Please login to the form below

Not currently logged in
Email:
Password:

thyroid cancer

This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed late-stage trials in thyroid cancer and lung ... National Cancer Institute (NCI) in the US, the

Latest news

  • FDA gives Loxo breakthrough tag for second cancer drug FDA gives Loxo breakthrough tag for second cancer drug

    including patients with brain metastases, and a 45% response rate in thyroid cancer. ... said. “Given the many available therapies for NSCLC and medullary thyroid cancer, we are pleased that LOXO-292 has shown encouraging data in refractory patients,

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    Eisai’ s Lenvima wins European liver cancer indication. EC green-lights the RTK inhibitor as a first-line treatment. ... Lenvima however, is already on the European market to treat thyroid cancer, but thanks to positive data from the phase III REFLECT

  • New cancer drugs can’t quite plug the revenue hole at AZ New cancer drugs can’t quite plug the revenue hole at AZ

    There was one blip on the pipeline radar for AZ however, as it revealed in its interim update that thyroid cancer candidate selumetinib had failed a phase III trial in thyroid ... cancer. The MEK inhibitor had previously failed in a late-stage lung

  • Loxo, Bayer get quick FDA review for ‘precision’ cancer drug Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

    biomarker, a departure from the usual regulatory route of seeking approval based on the organ or tissue where the cancer starts to grow. ... NTRK fusions are seen in a broad range of tumour types, including various forms of colorectal, lung, thyroid,

  • $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

    First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been ... A second cohort of endometrial cancer patients had an

More from news
Approximately 10 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal

  • EATRIS and the new age of partnering EATRIS and the new age of partnering

    In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and Iressa (gefitinib), an epidermal growth factor receptor tyrosine kinase ... 2 trials for NSCLC, and

  • Pharma deals during August 2013 Pharma deals during August 2013

    In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “ holy

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics